In 1900, for every 1,000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The National Childhood Vaccine Injury Act, passed in 1986, was intended to bolster vaccine research and development through the federal coordination of vaccine initiatives and to provide relief to vaccine manufacturers facing financial burdens. The legislation also intended to address concerns about the safety of vaccines by instituting a compensation program, setting up a passive surveillance system for vaccine adverse events, and by providing information to consumers. A key component of the legislation required the U.S. Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse events, especially in children. Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health events associated with specific vaccines covered by the National Vaccine Injury Compensation Program (VICP), including the varicella zoster vaccine, influenza vaccines, the hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews peer-reviewed primary studies, summarizes their findings, and evaluates the epidemiological, clinical, and biological evidence. It finds that while no vaccine is 100 percent safe, very few adverse events are shown to be caused by vaccines. In addition, the evidence shows that vaccines do not cause several conditions. For example, the MMR vaccine is not associated with autism or childhood diabetes. Also, the DTaP vaccine is not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma. Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the VICP, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors.

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series

THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad.

Chronic liver failure is a frequent condition in clinical practice that encompasses all manifestations of patients with end-stage liver diseases. Chronic liver failure is a multiorgan syndrome that affects the liver, kidneys, brain, heart, lungs, adrenal glands, and vascular, coagulation, and immune systems. Chronic Liver Failure: Mechanisms and Management covers for the first time all aspects of chronic liver failure in a single book, from pathogenesis to current management. Each chapter is written by a worldwide known expert in their area and all provide the latest state-of-the-art knowledge. This volume is specifically designed to provide answers to clinical questions to all doctors dealing with patients with liver diseases, not only clinical gastroenterologists and hepatologists, but also to internists, nephrologists, intensive care physicians, and transplant surgeons.

Studies on Hepatitis Viruses: Life Cycle, Structure, Functions, and Inhibition presents the latest on this systemic infection that predominantly affects the liver with inflammation that can be acute or chronic. Hepatitis viruses have been the subject of intense study in the last twenty years, with a wealth of information related to their lifecycle, structure, functions and inhibition being presented. This book compiles the most important developments and research, giving users a very useful guide on this evolving area of virology and medicinal chemistry. - Provides comprehensive, state-of-the-art coverage of hepatitis virus infections, the virus' lifecycle, and mechanisms of protease inhibition - Analyzes structure-activity relationships of inhibitors of viral hepatitis - Presents an in-depth view of the structure and function of viral hepatitis - Discusses classification, epidemiology, pathogenesis, natural history, clinical manifestations, diagnosis, complications, associated disorders and animal models

The AAP's authoritative guide on preventing, recognizing, and treating more than 200 childhood infectious diseases. Developed by the AAP's Committee on Infectious Diseases as well as the expertise of the CDC, the FDA, and hundreds of physician contributors.

Hepatitis A is a major health concern throughout the world. Its impact has largely been limited in recent times by the large-scale use of vaccines. It is, however, still rampant in various parts of the world, partly due to lack of medication, poor water access, and contaminated food products. This book provides comprehensive information on various aspects of hepatitis A with a focus on three of the most important biliary diseases: cholestasis, primary sclerosing cholangitis, and hemophagocytic lymphohistiocytosis. Chapters cover such topics as pathology, epidemiology, at-risk populations, animal research models, and future trends.

"A subject collection from Cold Spring Harbor Perspectives in Medicine"--title page.

The last few years have witnessed major developments in molecular biology which have had a significant impact on biomedical knowledge. As a result new concepts in cell biology have emerged, new etiologic agents have been discovered, and new drugs have become available. Furthermore, the world of mediators, cytokines, and humoral factors has enlarged considerably in a relatively short period and this has modified our views of diverse physio pathologic processes as well as opened up new therapeutic prospects. In addition, recent technologic advances have revolutionized our diagnostic methodology and have greatly enhanced the power of our therapeutic resources. All these factors have contributed to a substantial remodeling of both liver science and clinical hepatology, and these changes have generated the motivation for the production of the present book, which attempts to give an account of well-known clinical facts in the light of current thinking. It is the fruit of the coordinated work of experts from different countries in three continents. In a sense, it is a manifestation of the fact that inter national cooperation is becoming increasingly important not only in the expansion of science but also in its exposition. We hope that Hepatobiliary Diseases will be useful to both students and clinicians and that internists, gastroenterologists, and general practitioners will find in its contents a satifactory coverage of their field of interest.

In consultation with Consulting Editor, Dr. Alan Buchman, Dr. Stanley J. Naides has put together a state-of the-art issue of the Gastroenterology Clinics of North America devoted to Laboratory Monitoring of Gastrointestinal and Hepatobiliary Disease. Clinical review articles from expert authors are specifically devoted to the following: Inborn Errors of Metabolism and the GI track; Primary Immunodeficiency and the gut; Liver fibrosis determination; IBD; Autoimmune liver disease diagnosis and classification; Laboratory Diagnosis of Viral hepatitis; IgG4-RD with Emphasis on its GI Manifestation; Bowel Microbiome in Health and Disease; AAV System; and Celiac Disease. Readers will come away with the latest information they need to diagnose and monitor patients with gastrointestinal and hepatobiliary disease.